Coronavirus: Vaccination

(asked on 4th January 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of vaccinating children aged five to 11 against covid-19 who (a) have complex respiratory and neurological conditions that make them more vulnerable to severe illness from covid-19 and (b) are clinically extremely vulnerable for other reasons; and whether that is a priority for his Department.


Answered by
Maggie Throup Portrait
Maggie Throup
This question was answered on 12th January 2022

On 22 December 2021, the Joint Committee on Vaccination and Immunisation (JCVI) provided advice on the primary vaccination of five to 11 year olds. The potential merits from vaccination were assessed according to the presence or absence of underlying health conditions that increase the risk of serious COVID-19. It advised that children aged five to 11 years in a clinical risk group, which includes complex respiratory and neurological conditions, or who were household contacts of someone who is immunosuppressed should be offered two 10 micrograms doses of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) with an interval of eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent COVID-19 infection should be four weeks. Further advice regarding COVID-19 vaccination for other five to 11 year olds will be issued in due course following consideration of additional data.

Reticulating Splines